<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707365</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190090</org_study_id>
    <secondary_id>IDRCB :2019-A00071-56</secondary_id>
    <nct_id>NCT04707365</nct_id>
  </id_info>
  <brief_title>Microenvironment and Immunity of Digestive Cancers - East Paris Multicentric Cohort</brief_title>
  <acronym>MICADO</acronym>
  <official_title>Interactions Between Tumor, Tumor Microenvironment and Immune System in Digestive Cancers : Impact on Survival and Response to Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal and pancreatobiliary cancers are the most common digestive cancers. Their&#xD;
      incidence has particularly increased over the last few decades, leading to suspicion that&#xD;
      environmental factors are involved. In addition, strategies for the therapeutic management of&#xD;
      these cancers are evolving in the context of the development of immunotherapies.&#xD;
&#xD;
      Tumor microenvironment is a potential source of new diagnostic, prognostic and predictive&#xD;
      markers and new therapeutic targets. The links between tumor microenvironment and modulation&#xD;
      of the immune system in colorectal and pancreatobiliary cancers are poorly understood.&#xD;
      Molecular classifications have been proposed for these cancers, but their link with immunity&#xD;
      and response to treatment remains to be explored.&#xD;
&#xD;
      Objective : explore links between molecular subtypes, tumor microenvironment, host (immune&#xD;
      system, pre-metastatic niche, intestinal microbiota, metabolism), and survival (prognostic&#xD;
      value), response (predictive value) and tolerance (toxicities) to treatments in digestive&#xD;
      cancers, in particular colorectal and pancreatobiliary cancers.&#xD;
&#xD;
      Method: Retrospective and prospective monocentric cohort study&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">March 2035</completion_date>
  <primary_completion_date type="Anticipated">March 2035</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Retrospective and prospective monocentric cohort study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>observation from first cancer treatment date until date of death or 10 years follow up if patient alive</time_frame>
    <description>Overall survival (OS): vital status (alive/deceased)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Pancreas Tumor</condition>
  <condition>Biliary Tract Tumor</condition>
  <condition>Immune System and Related Disorders</condition>
  <arm_group>
    <arm_group_label>digestive cancers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colorectal and pancreatobiliary cancers</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tumor samples</intervention_name>
    <description>for each patient: liver sampling, blood samples ( serum, plasma, PBMC, whole blood), per-endoscopic bile sampling, stool samples, and materials derived from fresh tumors</description>
    <arm_group_label>digestive cancers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Colorectal or pancreatic adenocarcinoma or biliary tract adenocarcinoma&#xD;
&#xD;
          -  Cytologically or histologically proven adenocarcinoma, regardless of stage and&#xD;
             treatment&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Diagnosed from 2015 onwards&#xD;
&#xD;
          -  Signed Consent&#xD;
&#xD;
          -  Affiliation to a social security scheme (including CMU (Universal health coverage))&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under guardianship, curatorship or safeguarding of justice&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Any medical, psychological or social situation that could prevent compliance with the&#xD;
             protocol according to the investigator's assessment.&#xD;
&#xD;
          -  Refusal to participate in the study&#xD;
&#xD;
          -  Patient on AME (state medical assistance)&#xD;
&#xD;
          -  Persons deprived of liberty by a judicial or administrative decision&#xD;
&#xD;
          -  Persons under psychiatric care&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pr Tournigand</last_name>
    <role>Study Director</role>
    <affiliation>AP-HP Henri Mondor Créteil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christophe Tournigand, MD-PHD</last_name>
    <phone>0149812567</phone>
    <phone_ext>0033</phone_ext>
    <email>christophe.tournigand@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ilaria Cascone, PHD</last_name>
    <phone>0149813765</phone>
    <phone_ext>0033</phone_ext>
    <email>ilaria.cascone@u-pec.fr</email>
  </overall_contact_backup>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>AP-HP is the owner of the data and no use or transmission to a third party may be made without its prior consent.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

